Floatz logo

Rucaparib

Ovarian Cancer

pharmaand GmbHSmall moleculePhase 3Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
59/ 100

Competitive context

512 Active assets in the Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
TIL
Inge Marie Svane
Phase 2BB
Olaparib
Shandong University
Phase 4BB
Cis-Diamminedichloroplatinum Ii
Kalinski, Pawel, MD, PhD
Phase 3BB
Adriamycin
Genmab
Phase 3BB

View all 50 →

Same molecule, other indications

Rucaparib is also rated in:

peritoneum cancerActive
BB
Indicative · Phase 3
66 / 100
View asset →
ovarian carcinomaActive
B
Indicative · Phase 3
61 / 100
View asset →
fallopian tube cancerActive
B
Indicative · Phase 3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →